[ad_1] SAN DIEGO – Bexagliflozin was effective and well-tolerated in lowering hemoglobin A1 C in patients with diabetes and stage 3a / 3b CKD, according to ASN Kidney Week. "We run into …
Read More »Janssen terminates Canagliflozin's CREDENCE test soon after reaching T2D, CKD Endpoints
[ad_1] Vlado Perkovic, PhD Janssen Pharmaceutical Johnson & Johnson companies announced the early end of a phase 3 of canagliflozin (Invokana) for the treatment of patients with chronic renal failure and type …
Read More »